These findings suggest that RIDad promotes an immunosuppressive tumor microenvironment through an upregulation of IDO1 in yet to be identified cell types as well as an augmented recruitment of immunomodulatory TAMs, rather than through direct alterations in other immune cell populations. The gene discussed is IDO1; the disease is neoplasm.